Sale!

Immunohistochemistry PD-L1 SP263 Ventana Test

790 د.إ

-9%

The Immunohistochemistry PD-L1 SP263 Ventana Test is a specialized diagnostic procedure performed at DNA Labs UAE, aimed at detecting the presence of the Programmed Death-Ligand 1 (PD-L1) protein in cancer cells. PD-L1 is a protein that, when expressed on the surface of cancer cells, can help them evade the immune system. This test uses the SP263 clone in the Ventana platform, a precise and reliable method for assessing PD-L1 expression. It is particularly valuable in determining the suitability of patients for certain immunotherapies that target the PD-1/PD-L1 pathway, which is a critical axis in the immune response to cancer. By identifying patients whose tumors express PD-L1, clinicians can better tailor treatment plans to leverage the benefits of immune checkpoint inhibitors. The cost of the test at DNA Labs UAE is 790 AED, providing a crucial service for patients and healthcare providers in the region, enhancing personalized cancer treatment strategies.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

IMMUNOHISTOCHEMISTRY PD-L1 SP263 VENTANA Test

Cost: AED 790.0

Are you looking for information about the IMMUNOHISTOCHEMISTRY PD-L1 SP263 VENTANA Test? Look no further! DNA Labs UAE offers this test at a cost of AED 790.0. Read on to learn more about the test, its components, and how it can help in diagnosing cancer.

Test Name: IMMUNOHISTOCHEMISTRY PD-L1 SP263 VENTANA Test

Components: The test costs AED 790.0 and requires a tumor tissue sample submitted in 10% Formal-saline or a Formalin fixed paraffin embedded block. The sample should be shipped at room temperature. Additionally, a copy of the Histopathology report, the site of biopsy, and the patient’s clinical history should be provided.

Report Delivery:

Sample: Daily by 6 pm

Report Block: 5 days

Tissue Biopsy: 5 days

Tissue large complex: 7 days

Method:

Immunohistochemistry

Test Type:

Cancer

Doctor:

Oncologist, Pathologist

Test Department:

HISTOLOGY

Pre Test Information:

A copy of the Histopathology report, the site of biopsy, and the patient’s clinical history should be provided.

Test Details:

The PD-L1 SP263 test is an immunohistochemistry (IHC) test used to evaluate the expression of the PD-L1 protein in tumor tissue samples. It is performed using the Ventana PD-L1 SP263 assay, which is a specific antibody designed to detect PD-L1.

PD-L1 is a protein that is expressed on the surface of tumor cells and some immune cells. It plays a crucial role in regulating the immune response by interacting with its receptor PD-1 on T cells. When PD-L1 binds to PD-1, it inhibits the activity of T cells, allowing the tumor to evade immune attack.

The PD-L1 SP263 test is commonly used in cancer research and clinical practice, particularly in the field of immuno-oncology. It helps determine the level of PD-L1 expression in tumor cells, which can guide treatment decisions for patients with certain types of cancer.

The test involves staining tumor tissue sections with the PD-L1 SP263 antibody, followed by visualization using an automated staining system. The staining intensity and percentage of PD-L1 positive tumor cells are evaluated by a pathologist, who assigns a score based on predefined criteria. This score can then be used to classify tumors as PD-L1 positive or negative.

The PD-L1 SP263 test is used as a predictive biomarker for response to immune checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors. Tumors with high levels of PD-L1 expression are more likely to respond to these therapies, as blocking the PD-1/PD-L1 interaction can enhance the anti-tumor immune response.

It is important to note that the PD-L1 SP263 test is just one of several available assays for PD-L1 testing, and different assays may have different scoring systems and cutoffs for determining PD-L1 positivity. Therefore, the results of the PD-L1 SP263 test should be interpreted in conjunction with other clinical and pathological factors.

Test Name IMMUNOHISTOCHEMISTRY PD-L1 SP263 VENTANA Test
Components
Price 790.0 AED
Sample Condition Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days
Method Immunohistochemistry
Test type Cancer
Doctor Oncologist, Pathologist
Test Department: HISTOLOGY
Pre Test Information Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details

The PD-L1 SP263 test is an immunohistochemistry (IHC) test used to evaluate the expression of the PD-L1 protein in tumor tissue samples. It is performed using the Ventana PD-L1 SP263 assay, which is a specific antibody designed to detect PD-L1.

PD-L1 is a protein that is expressed on the surface of tumor cells and some immune cells. It plays a crucial role in regulating the immune response by interacting with its receptor PD-1 on T cells. When PD-L1 binds to PD-1, it inhibits the activity of T cells, allowing the tumor to evade immune attack.

The PD-L1 SP263 test is commonly used in cancer research and clinical practice, particularly in the field of immuno-oncology. It helps determine the level of PD-L1 expression in tumor cells, which can guide treatment decisions for patients with certain types of cancer.

The test involves staining tumor tissue sections with the PD-L1 SP263 antibody, followed by visualization using an automated staining system. The staining intensity and percentage of PD-L1 positive tumor cells are evaluated by a pathologist, who assigns a score based on predefined criteria. This score can then be used to classify tumors as PD-L1 positive or negative.

The PD-L1 SP263 test is used as a predictive biomarker for response to immune checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors. Tumors with high levels of PD-L1 expression are more likely to respond to these therapies, as blocking the PD-1/PD-L1 interaction can enhance the anti-tumor immune response.

It is important to note that the PD-L1 SP263 test is just one of several available assays for PD-L1 testing, and different assays may have different scoring systems and cutoffs for determining PD-L1 positivity. Therefore, the results of the PD-L1 SP263 test should be interpreted in conjunction with other clinical and pathological factors.